prednisone has been researched along with quinazolines in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silver, R | 1 |
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Evens, A; Osborne, CK | 1 |
| Carreres-Prieto, M; Layos-Romero, L; López-Sisamón, D | 1 |
| Aguiar, W; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Franco, M; Gerbase de Lima, M; Hannun, P; Medina-Pestana, J; Sandes-Freitas, T; Tedesco-Silva, H | 1 |
| Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A | 1 |
2 trial(s) available for prednisone and quinazolines
| Article | Year |
|---|---|
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
4 other study(ies) available for prednisone and quinazolines
| Article | Year |
|---|---|
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; Fertility Preservation; Humans; Lapatinib; Lymphoma; Molecular Targeted Therapy; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Receptor, ErbB-2; Rituximab; Trastuzumab; Vinblastine; Vincristine | 2011 |
[Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Lung Diseases, Interstitial; Male; Organoplatinum Compounds; Oxaliplatin; Prednisone; Quinazolines; Thiophenes | 2015 |
Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Topics: Adult; Antibodies; Cohort Studies; Drug Interactions; Drug Substitution; Everolimus; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Pyrroles; Quinazolines; Tacrolimus | 2016 |